Hundreds of lawsuits claim Ozempic, Wegovy and Mounjaro GLP-1 drugs caused permanent vision loss
AI مارکیٹ کا خلاصہ
Hundreds of lawsuits allege GLP-1 drugs (including Novo Nordisk's Ozempic/Wegovy and Eli Lilly's Mounjaro/Zepbound) caused NAION-related vision loss and that warnings were insufficient in the US. Rising claim volume and litigation risk can increase uncertainty around product safety, labeling, and potential settlement or regulatory costs, pressuring near-term risk appetite toward affected pharma equities and related healthcare exposure.
اثر کی سطح
● درمیانہ
متاثرہ اثاثے
NCSKNVO2USD/USDT-1.02%
AI تجزیاتی سمجھ · NCSKNVO2USD/USDTAI تجزیاتی سمجھ
▼ Bearish
ابھی ٹریڈ کریں
⚠️ AI سے تیار کردہ تجزیاتی سمجھ خبروں کے مواد پر مبنی ہے اور صرف معلوماتی مقاصد کے لیے فراہم کی گئی ہے۔ یہ سرمایہ کاری کا مشورہ نہیں ہے اور نہ ہی BingX کے خیالات کی نمائندگی کرتی ہے۔ سرمایہ کاری میں رسک شامل ہے۔ براہ کرم ذمہ داری سے ٹریڈ کریں۔
Hundreds of lawsuits accuse Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and other GLP-1 drugs of causing permanent vision loss. Plaintiffs argue the companies should have known about the risk but did not disclose it on U.S. warning labels. One 63-year-old man with diabetes allegedly lost vision in one eye after taking Ozempic and later became legally blind, and a Phoenix law firm says it has received nearly 200 inquiries, with some cases filed in states including Arizona.
